Cognitive Improvements in Patients with Mild Cognitive Impairment and Alzheimer’s Disease through a Personalized Mito Food Plan Diet and Cell Repair Therapy
Nicole C Hank1, Jonathon Pereira2, Brandon McCravey1, Laura Christians1, Chelsea Hoggan2, Fabrice Dechoux2
1Department of Neurology, Perseverance Research Center, LLC, 11000 North Scottsdale Road, 110, Scottsdale, USA
2Cerulean Advanced Wellness and Fitness, 9150 E Del Camino Dr 101, Scottsdale, USA
Read the full manuscript here.
Abstract
Objective: Currently, over 50 million people worldwide are diagnosed with Alzheimer’s Disease and more than 16 million Americans suffer from Mild Cognitive Impairment. Despite unremitting scientific and clinical efforts, there has yet to be therapy that has abated disease progression. In the last two decades, clinical trials have focused on beta amyloid (Aβ), which has been known to play a key role in the pathogenesis of AD; however, drug therapies in AD research have had a 99.6% failure rate.
Methods: Each patient followed a personalized Mito Food Plan, designed based on individual assessments, including Resting Metabolic Rate (RMR), Respiratory Quotient (RQ), and Metabolic Efficiency (ME) as measured through RMR testing. Macronutrient intake was tailored to each subject’s physiological profile, and participants maintained a daily diet diary, reviewed at each visit. Additionally, four of the five subjects opted to undergo adjunctive Cellular Repair Therapy, which consisted of treatment with the NanoVi® device, manufactured by Eng3. Therapy was administered for 30 minutes, three times a week, over 12 weeks.
Results: Improvements in cognitive testing scores and QOL were correlated to decreased inflammation.
Conclusion: Results suggest cognition can improve with the decrease of chronic inflammation in those with cognitive impairments.
